Soccer video and player position dataset

This paper presents a dataset of body-sensor traces and cor-responding videos from several professional soccer games captured in late 2013 at the Alfheim Stadium in Tromsø, Norway. Player data, including field position, heading, and speed are sampled at 20 Hz using the highly accurate ZXY Sport Tracking system. Additional per-player statistics, like total distance covered and distance covered in different speed classes, are also included with a 1 Hz sampling rate. The pro-vided videos are in high-definition and captured using two stationary camera arrays positioned at an elevated position above the tribune area close to the center of the field. The camera array is configured to cover the entire soccer field, and each camera can be used individually or as a stitched panorama video. This combination of body-sensor data and videos enables computer-vision algorithms for feature ex-traction, object tracking, background subtraction, and sim-ilar, to be tested against the ground truth contained in the sensor traces

Solsensor design og testing til Orbit NTNUs CubeSat

Bachelor-gruppen har hatt som mål å designe og kalibrere en prototype solsensor med Field of View på 60°. Solsensorer er kommersielt sett veldig kostbare, av denne grunnen ønsker Orbit å designe og produsere disse in-house. For å oppnå dette har gruppen forsket på teorien bak forskjellige tilnærminger til problemet, og gjennom vårsemesteret 2021 designet en solsensor som er basert på en fire-kvadrant lysdiode. Selve sensoren kalibreres med en kalibreringsrigg med to frihetsgrader som er av gruppens eget design, og i tillegg til dette har gruppen en rekke andre kostnadsbesparende løsninger. Gruppen har simulert forventet resultater i MATLAB, og legger fram de faktiske målingene fra sensoren. Deretter diskuteres og sammenlignes disse, og gruppen konkluderer med at oppgaven er fullt gjennomførbar, men at noen uheldige omstendigheter gjorde at målet ikke ble fullstendig nådd. Som siste del av rapporten skrives det om framtidig arbeid, og hva gruppen mener Orbit bør gjøre som neste steg i prosessen

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial

International audienceAbstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, placebo-controlled trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients with severe/critical COVID-19 were randomised to Baricitinib 4 mg once daily or placebo, added to standard of care. The primary endpoint was all-cause mortality within 60 days. Participants were remotely followed to day 90 for safety and patient related outcome measures. Results Two hundred ninety-nine patients were screened, 284 randomised, and 275 received study drug or placebo and were included in the modified intent-to-treat analyses (139 receiving baricitinib and 136 placebo). Median age was 60 (IQR 49–69) years, 77% were male and 35% had received at least one dose of SARS-CoV2 vaccine. There were 21 deaths at day 60 in each group, 15.1% in the baricitinib group and 15.4% in the placebo group (adjusted absolute difference and 95% CI − 0.1% [− 8·3 to 8·0]). In sensitivity analysis censoring observations after drug discontinuation or rescue therapy (tocilizumab/increased steroid dose), proportions of death were 5.8% versus 8.8% (− 3.2% [− 9.0 to 2.7]), respectively. There were 148 serious adverse events in 46 participants (33.1%) receiving baricitinib and 155 in 51 participants (37.5%) receiving placebo. In subgroup analyses, there was a potential interaction between vaccination status and treatment allocation on 60-day mortality. In a subsequent post hoc analysis there was a significant interaction between vaccination status and treatment allocation on the occurrence of serious adverse events, with more respiratory complications and severe infections in vaccinated participants treated with baricitinib. Vaccinated participants were on average 11 years older, with more comorbidities. Conclusion This clinical trial was prematurely stopped for external evidence and therefore underpowered to conclude on a potential survival benefit of baricitinib in severe/critical COVID-19. We observed a possible safety signal in vaccinated participants, who were older with more comorbidities. Although based on a post-hoc analysis, these findings warrant further investigation in other trials and real-world studies. Trial registration Bari-SolidAct is registered at NCT04891133 (registered May 18, 2021) and EUClinicalTrials.eu ( 2022-500385-99-00 )